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Background. Patients on chronic intermittent renal replacement therapy (RRT) are at risk for infection with carbapenem-re-
sistant Enterobacteriaceae (CRE). However, the impact of RRT on outcomes after CRE infections remains to be defined. Here we 
perform a comparison of outcomes for CRE-infected patients with preserved renal function compared with CRE-infected patients 
on RRT.
Methods. Cases and controls were defined from a prospective cohort of CRE-infected patients from the Consortium on 
Resistance against Carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE). Cases were defined as CRE-infected 
patients on RRT at hospital admission, while controls were defined as CRE-infected patients with serum creatinine <2 mg/dL and 
not receiving RRT at admission. Risk factors for 28-day in-hospital mortality were assessed using multivariable logistic regression. 
An ordinal ranking of outcomes by desirability analysis was performed.
Results. Patients on RRT were more likely to have diabetes mellitus and cardiac disease than controls. Urinary sources of infec-
tion were less common in the RRT group. In RRT patients, 28-day in-hospital mortality was increased as compared with controls: 
22/71 (31%) vs 33/295 (11%). RRT remained significantly associated with 28-day in-hospital mortality after adjustment for source 
of infection, prehospitalization origin, and severity of illness (adjusted odds ratio, 2.27; 95% confidence interval [CI], 1.09–4.68; 
P =  .03). Using univariable desirability of outcome ranking analysis, RRT status was associated with a 68% (95% CI, 61%–74%) 
chance of a worse disposition outcome.
Conclusions. Chronic RRT in CRE-infected patients is associated with increased in-hospital mortality and worse disposition 
outcomes at 28 days.
Keywords. carbapenem-resistant Enterobacteriaceae; Klebsiella pneumoniae; mortality; renal failure; renal replacement therapy. 
Nearly 500 000 Americans with end-stage renal disease (ESRD) 
required chronic intermittent renal replacement therapy (RRT) 
in 2013. Prevalence rates are rising, with more than 100  000 
new patients initiating chronic RRT in 2013 [1]. RRT patients 
typically engage with the health care setting 3 times weekly 
and face more than 1.5 hospital admissions/person-year [2]. 
The majority (79%) of ESRD patients initiate hemodialysis via 
intravascular catheter, which increases the risk for line-related 
bloodstream infection [3]. According to a meta-analysis, RRT 
patients face intravenous antibiotic start rates ranging from 
3.1–7.7 per 100 patient-months [4].
ESRD is associated with impaired innate and adaptive 
immune responses [5, 6]. In addition, ESRD may lead to bac-
terial overgrowth, particularly in the duodenum and jejunum 
[7]. Beyond increased bacterial counts in the gut, an increase 
in abundance of potentially pathogenic bacterial families such 
as Enterobacteriaceae is observed. This occurs at the expense of 
Lactobacillaceae and Prevotellaceae, both normal components 
of healthy gut flora [8].
These increased opportunities for acquisition in ESRD 
patients translate into higher incidence of infection with mul-
tidrug-resistant organisms than the general population, par-
ticularly methicillin-resistant Staphylococcus aureus (MRSA) 
and vancomycin-resistant Enterococci (VRE) [9]. There are no 
published studies of incidence of CRE infections in the ESRD 
population. Outcomes of CRE infections in ESRD patients 
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on RRT are also poorly studied. In a sample in which gram- 
negative bacteria comprised 52% of the cases, 30-day mortality 
of 15.1% was observed among patients with ESRD on RRT [10]. 
Compared with patients not on RRT, ESRD patients on RRT 
face mortality rates more than 2 times higher for sepsis, pneu-
monia, and endocarditis [11–13]. ESRD patients on RRT are 
also more likely to die from antibiotic-resistant organisms such 
as MRSA (adjusted odds ratio [aOR], 5.4; 95% confidence inter-
val [CI], 1.5–18.7) and Clostridium difficile (aOR, 2.15; 95% CI, 
2.07–2.24) [14, 15]. For CRE, 1 study identified a median sur-
vival of 1 month for CRE-infected patients with ESRD on RRT 
compared with more than 24 months for the control group of 
ESRD patients on RRT without infection [16]. The aim of this 
study was to examine outcomes in CRE-infected patients on 
RRT compared with CRE-infected patients with normal renal 
function in a large prospective, multicenter cohort of CRE-
infected patients.
METHODS
Patients
The Consortium on Resistance against Carbapenems in 
Klebsiella and other Enterobacteriaceae (CRACKLE) is a pro-
spective, multicenter, observational study of hospitalized 
patients with CRE in the Great Lakes Region of the United States 
[17–20]. The study period for the current study was December 
2011 to July 2016. Two nonoverlapping nested cohorts of 
patients with CRE infection were constructed. Patients who 
did not meet criteria for infection and were deemed to have 
CRE colonization were excluded. Standardized, a priori defini-
tions of infection were used, as previously described [21]. The 
first cohort (“RRT patients”) contained all patients who were 
on RRT at the time of admission for the index hospitalization. 
The second cohort (“control patients”) consisted of all patients 
who did not have renal failure upon or during hospital admis-
sion. Renal failure was defined as either a need for RRT and/or 
a serum creatinine >2 mg/dL. In both cohorts, unique patients 
were included only once, at the time of their first CRE infection. 
All the health systems involved in this study had approval from 
their respective institutional review boards.
Microbiology
CRE was defined as Enterobacteriaceae isolates with nonsus-
ceptibility to any of the following carbapenems: meropenem, 
imipenem, or ertapenem, as outlined by the Clinical and 
Laboratory Standards Institute (CLSI) [22]. Bacterial identi-
fication and routine antimicrobial susceptibility testing was 
performed with MicroScan (Siemens Healthcare Diagnostics) 
or Vitek2 (bioMérieux) at the clinical sites. Additional suscepti-
bilities were obtained by GN4F Sensititre tray (Thermo Fisher) 
or Etest (bioMérieux), as indicated. In more than 90% of tested 
isolates, carbapenem resistance was mediated through blaKPC-2 
or blaKPC-3, as previously described [18, 19].
Clinical Data
Clinical data from the electronic medical record were entered 
into a centralized database. The index hospitalization was 
defined as the first hospital stay within the study period dur-
ing which a CRE infection occurred. Critical illness was 
determined as a Pitt bacteremia score ≥4 points on the day 
of the index culture [23]. The Pitt bacteremia score has pre-
viously been validated for nonbacteremic infections [24]. The 
Charlson comorbidity index was calculated at hospital admis-
sion, as described [25]. Outcomes at 28 days after the date of 
the index culture were categorized as follows: discharged home, 
discharged to a skilled nursing facility, remains admitted, dis-
charged to long-term acute care hospital (LTACH), dead or 
discharged to hospice. For this purpose, the status at hospital 
discharge was carried forward, and patients who were trans-
ferred to another hospital prior to the 28-day mark were con-
sidered “remains admitted.”
Statistics
Differences between groups were analyzed using the Wilcoxon 
rank sum test for continuous variables. Fisher’s exact test and 
Pearson testing were used for categorical variables where appro-
priate. Nominal logistic regression was performed to determine 
the univariable association of each variable of interest and 
28-day in-hospital mortality. All variables that were associ-
ated at a level of P <.1 were included in a multivariable model. 
An ordinal outcome was constructed based on the 28-day 
outcomes, with the following order of categories: “discharged 
home” (best), “discharged to skilled nursing facility,” “remains 
admitted,” “discharged to long-term acute care hospital,” “dead 
or discharged to hospice” (worst) [26]. P values of ≤.05 were 
considered statistically significant. JMP 10.0.1 software (SAS, 
Inc, Cary, NC) was used for all analyses.
RESULTS
Patient Characteristics
The study population included 71 case patients with end-stage 
renal disease (ESRD) requiring RRT and 295 control patients 
without renal failure, selected as shown in Figure 1. Carbapenem-
resistant Klebsiella pneumoniae comprised 90% of infections 
(n = 330). In the remaining 10% of patients, Enterobacter spp. 
(n = 20; 5%), Morganella morgannii (n = 6; 2%), Proteus mira-
bilis (n = 3; 1%), Providencia stuartii (n = 3; 1%), Escherichia 
coli (n  =  2; 1%), and Citrobacter spp. (n  =  2; 1%) were iso-
lated. The characteristics of the study population are shown in 
Table  1. The distributions of age, sex, and race did not differ 
significantly between the RRT and control groups. Besides renal 
failure, other comorbid conditions were also more common in 
RRT patients. Specifically, diabetes mellitus (DM) and cardiac 
disease were associated with the RRT group; the rates of DM 
and cardiac disease were 62% and 63% in RRT patients, respec-
tively, compared with 37% and 34%, respectively, in the control 
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group (P < .0001 for both). The distribution of infections also 
differed between the groups (P  =  .01), which was primarily 
driven by a higher proportion of urinary tract infections in the 
control group (34%) compared with the RRT population (14%). 
Furthermore, the 2 groups varied significantly by origin at time 
of admission, with 40% of control patients admitted from home 
compared with 30% of RRT patients and 5% of control patients 
admitted from LTACH compared with 20% of RRT patients.
Antibacterial Treatment
Directed anti-CRE treatment given within 14 days after index 
culture is summarized in Table  2. Upon comparison of the 
usage of specific antibiotics, colistin use was more common in 
the RRT group, with 23/71 (32%) receiving colistin as compared 
with 25/295 (8%) in the control patients (P < .0001). Other spe-
cific antibiotic usage was not different between groups. Of note, 
critical illness was more common in patients treated with colis-
tin; 28/48 (58%) patients who received colistin were critically ill, 
as compared with 119/318 (37%) patients who did not receive 
colistin (P < .01). Furthermore, colistin use was more common 
in patients with bloodstream infections (22/92; 24%), com-
pared with patients with other types of infection (26/274; 9%; 
P  =  .001). Similar proportions of cases and controls received 
agents without in vitro susceptibility to CRE.
Outcomes
Total length of stay of the index hospitalization was not different 
between RRT patients and control patients. The RRT group had 
illness of significantly higher severity at the time of first posi-
tive CRE culture. The impact of risk factors on 28-day mortality 
is shown in Table 3. The all-cause 28-day in-hospital mortality 
rates were 22/71 (31%) in RRT patients, compared with 33/295 
(11%) in control patients (P  <  .0001). Risk factors associated 
with increased mortality on multivariable analysis include 
bloodstream infection, transfer from hospital or LTACH, 
high levels of critical illness, and RRT. Notably, RRT remained 
Unique patients with
CRE recovered on culture
1049
565
Infected patients
427
Creatinine <2
on admission
295 controls
No acute
renal failure
132
Acute renal
failure
67
Not on
RRT
71 cases
Requiring
RRT
138
Renal failure
on admission
484
Colonized patients
Figure  1. Selection of isolates. Abbreviations: CRE, carbapenem-resistant 
Enterobacteriaceae; RRT, renal replacement therapy.
Table 1. Clinical Characteristics
All RRT Control Pa
n 366 71 295
Age, median (IQR), y 62 (50–74) 62 (53–71) 62 (49–75) .99
Female 189 (52) 36 (51) 153 (52) .90
Race .10
White 198 (54) 32 (45) 166 (56)
Black 140 (38) 35 (49) 105 (36)
Other 28 (8) 4 (6) 24 (8)
Charlson comorbidity index, 
 median (IQR)
3 (1–5) 6 (4–7) 2 (1–4) <.0001
Diabetes mellitus 152 (42) 44 (62) 108 (37) <.0001
Cardiac diseaseb 144 (39) 45 (63) 99 (34) <.0001
Type of infection .01
Bloodstream infection 92 (25) 21 (30) 71 (24)
Pneumonia 80 (22) 16 (23) 64 (22)
Urinary tract infection 109 (30) 10 (14) 99 (34)
Wound infection 40 (11) 11 (15) 29 (10)
Other infection 45 (12) 13 (18) 32 (11)
Origin <.01
Home 138 (38) 21 (30) 117 (40)
Skilled nursing facility 137 (37) 25 (35) 112 (38)
Hospital transfer 63 (17) 11 (15) 52 (18)
Long-term acute care hospital 28 (8) 14 (20) 14 (5)
Critical illnessc 147 (40) 39 (55) 108 (37) <.01
Length of stay, median (IQR), d 12 (7–24) 13 (9–24) 11 (6–25) .24
All data expressed as n (%), unless otherwise indicated. 
Abbreviations: IQR, interquartile range; RRT, renal replacement therapy.
aUnivariable relationship between variable of interest and RRT.
bCardiac disease defined as the presence of coronary artery disease and/or congestive 
heart failure.
cCritical illness defined as Pitt bacteremia score ≥4 at the time of index culture.
Table 2. Treatment Characteristics
All RRT Control Pa
n 366 71 295
Colistin 48 (13) 23 (32) 25 (8) <.0001
Tigecycline 117 (32) 22 (30) 95 (32) .88
Amikacin 58 (16) 13 (18) 45 (15) .59
Gentamicin 65 (18) 12 (17) 53 (18) 1.0
Trimethoprim/sulfamethoxazole 37 (10) 9 (13) 28 (9) .39
Carbapenem 130(36) 31 (44) 99 (34) .13
Fosfomycinb 16 (4) 1 (1) 15 (5) .33
Ceftazidime/avibactam 28 (8) 3 (4) 25 (8) .32
Antibiotics without in vitro anti-CRE 
activity
62 (17) 11 (15) 51 (17) .86
None of above 22 (7) 2 (3) 20 (7) .59
All data expressed as n (%), unless otherwise indicated. Shown is the number of patients 
who received a given antibiotic in the 14 days following index culture. Percentages accumu-
lated exceed 100% as patients may have received more than 1 antibiotic.
Abbreviations: CRE, carbapenem-resistant Enterobacteriaceae; RRT, renal replacement 
therapy.
aUnivariable relationship between variable of interest and RRT.
bFosfomycin use was only recorded in patients with urinary tract infections.
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significantly associated with 28-day in-hospital mortality after 
adjustment for source of infection, prehospitalization origin, 
and critical illness (aOR, 2.27; 95% CI, 1.09–4.68; P = .03).
The ordinal outcome of disposition at 28 days by desirability 
of outcome ranking (DOOR) analysis (dead/hospice, LTACH, 
admitted, nursing home, and home) is shown as a mosaic plot 
in Figure  2. The probability of a worse outcome in the RRT 
patient group was 68% (95% CI, 61%–74%) when compared 
with the control group.
DISCUSSION
In our cohort, CRE-infected patients receiving RRT have a 
higher likelihood of death and increased in-hospital mortal-
ity compared with controls, even after adjusting for source of 
infection, level of care at admission, infection type, and level 
of critical illness. RRT patients tended to have more comorbid 
conditions, which likely contributed to the observed increased 
hospital mortality. RRT patients with CRE infections were more 
likely to be admitted from higher levels of care than control 
patients and less likely than controls to be admitted from home. 
In addition, they are more acutely ill at the time of their CRE 
infection when compared with control patients with normal 
renal function. RRT patients also have a lower proportion of 
low-mortality urinary tract infections and higher proportions 
of bloodstream infections.
In addition, a DOOR analysis was performed to rank patients 
based on the range of possible dispositions following treatment 
of CRE infection [26]. In a DOOR analysis, when comparing 
outcomes between 2 groups, a likelihood of 50% of a worse 
outcome is indicative of no numerical difference between the 
groups. Similarly, if the 95% confidence interval crosses 50%, 
there is no statistically significant difference between the groups. 
In our study, the likelihood of a worse outcome for a patient in 
the RRT group as compared with a patient in the control group 
was 68%. DOOR analysis is a novel method of analyzing out-
comes on a spectrum of patient experiences. We have recently 
used DOOR analysis to compare patients treated with colistin vs 
ceftazidime-avibactam [27]. DOOR analysis provides an oppor-
tunity to analyze several states between alive and dead that are 
important to patients. In this study, we have used DOOR analysis 
to give a visual and statistical association between the exposure 
of interest (RRT in this case) and outcomes after CRE infection. 
While this is an association that does not imply causality, the 
robust observation of poor outcomes in this vulnerable patient 
population and the quantification of this effect add to the exist-
ing literature of impact of infections on patients with chronic 
renal failure. Furthermore, these findings add to existing studies 
to emphasize the clear need for infection control measures and 
antibiotic stewardship in patients on RRT [28].
RRT patients have been shown to have a higher risk for the 
acquisition of multidrug-resistant (MDR) organisms than 
patients with normal renal function. For instance, receipt of RRT 
Table 3. Risk Factors for 28-Day In-Hospital Mortality
Survivor Nonsurvivor Pa aOR 95% CI Pb
n 311 55
Age, median 
(IQR)
62 (49–74) 63 (53–74) .85
Female 161 (52) 28 (51) 1.0
Race .31
White 173 (56) 25 (45)
Black 114 (37) 26 (47)
Other 24 (8) 4 (7)
Charlson comor-
bidity index ≥3
160 (51) 31 (56) .56
Diabetes mellitus 128 (41) 24 (44) .77
Cardiac diseasec 120 (39) 24 (44) .54
Source <.0001 .001
Blood (ref.) 66 (21) 26 (47) - -
Urine 105 (34) 4 (7) 0.16 0.05–0.51
Respiratory 66 (21) 14 (25) 0.27 0.12–0.65
Other 74 (24) 11 (20) 0.39 0.16–0.92
Origin .001
Home (ref.) 122 (39) 15 (27) - -
Skilled nursing 
facility
125 (40) 12 (22) 0.63 0.26–1.48
Hospital transfer 49 (16) 15 (27) 1.93 0.81–4.66
Long-term acute 
care hospital
15 (5) 13 (24) 4.53 1.60–12.97
Critical illnessd 107 (34) 40 (73) <.0001 4.28 2.15–8.93 <.0001
RRT 49 (16) 22 (40) <.001 2.27 1.09–4.68 .03
All data expressed as n (% of survivors and nonsurvivors, respectively), unless otherwise 
indicated.
Abbbreviations: aOR, adjusted odds ratio; CI, confidence interval; IQR, interquartile range; 
RRT, renal replacement therapy.
aP value for univariable relationship with 28-day in-hospital mortality. 
bP value for multivariable relationship with 28-day in-hospital mortality. 
cCardiac disease defined as the presence of coronary artery disease and/or congestive 
heart failure.
dCritical illness defined as Pitt bacteremia score ≥4 at the time of index culture.
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Figure 2. Mosaic plot of outcomes at 28 days. If a patient was discharged prior 
to 28 days, the last observation was carried forward. Using desirability of outcome 
ranking analysis, renal replacement therapy patients had a 68% (95% confidence 
interval, 61%–74%) likelihood of a worse outcome at 28 days as compared with 
controls. Abbreviation: LTACH: long-term acute care hospital.
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was associated with an aOR of 2.34 for infection with ampC-car-
rying organisms [29]. More data exist for higher rates of infection 
with MRSA and VRE in the RRT population when compared 
with patients with normal renal function [30, 31]. Outcomes in 
resistant Enterobacteriaceae infections in the chronic RRT popu-
lation are rare in the literature. A 42-month study of French RRT 
patients showed that 42% developed any bloodstream infection 
during the study period, 32/93 experienced hospitalization or 
death, and isolation of an MDR pathogen was associated with an 
increased chance of hospitalization or death (OR, 2.75; 95% CI, 
1.01–7.48) [32]. An Israeli study found higher mortality in CRE-
infected patients than those infected with carbapenem-suscepti-
ble strains (OR, 1.9; 95% CI, 1.2–3.1). Thirty-day mortality was 
associated with several comorbid conditions, including dialy-
sis (OR, 5.6; 95% CI, 2.7–11.5) and chronic renal failure (OR, 
3.1; 95% CI, 1.9–5.1), though they did not compare RRT and 
non-RRT patients with CRE infections [33]. Bacteremic RRT 
patients in the United Kingdom experienced worse outcomes 
than bacteremic renal transplant patients in a setting where 
Enterobacteriaceae comprised the majority (57/77; 74%) of the 
infecting strains; of which 15/57 (26%) were ESBL-producing 
Enterobacteriaceae [34].
The difference in distribution of infections between the 2 
groups was driven primarily by the lower share of urinary tract 
infections in the RRT group; this finding is expected as 72% of 
RRT patients are anuric at 1 year from RRT initiation [35]. We 
have previously shown that within the various sources of CRE 
infection in hospitalized patients, bacteremia and pneumonia 
are associated with the highest mortality risk, and urinary tract 
infection the lowest [21]. Similarly, proportions of in-hospital 
mortality observed in patients with CRE urinary tract infec-
tions were similar to controls with CRE urinary tract coloniza-
tion [21]. Adjustment for source was, therefore, an important 
part of our multivariable analysis. Even after this adjustment, 
there was a large excess risk of death associated with RRT.
The increased use of colistin in the RRT population may have 
several explanations that are not mutually exclusive. First, it 
may reflect the acuity of illness at the time of index culture. An 
association between critical illness and colistin use was noted. 
In 1 study of colistin use in a 2200-bed health system, patients 
receiving colistin had high proportions of sepsis/severe sepsis/
septic shock (80%), mechanical ventilation (62%), and baseline 
renal insufficiency (25%), suggesting that colistin is used prin-
cipally in a critically ill population [36]. Second, a lack of con-
cern for nephrotoxicity in RRT patients may play a role. This 
is difficult to assess from the literature as no studies have spe-
cifically surveyed providers’ use of colistin. One study of anti-
biotic choice in health care–associated pneumonia treatment 
identified only duration of admission >5 days and Acinetobacter 
baumanii prevalence >10% in respiratory cultures as predictors 
of colistin use; renal replacement therapy was not a studied var-
iable; however, prevalence of chronic renal failure in the study 
population was 15% [37]. Furthermore, patients requiring any 
kind of renal replacement therapy including RRT are typically 
excluded from studies of colistin use. Third, colistin may be 
used more for specific infection types. We observed an associ-
ation between colistin use and bloodstream infections but not 
pneumonia, which may reflect a lower propensity for CRE to 
cause pneumonia as compared with Pseudomonas aeruginosa 
and Acinetobacter baumannii.
The study had several limitations as a result of its observa-
tional design and geographical origin. The etiology of carbape-
nem resistance in the hospitals studied is predominantly blaKPC; 
therefore, these results may not be generalizable to infecting 
isolates with other mechanisms of carbapenem resistance. 
Also, the study was conducted in the Great Lakes region of the 
United States, and other patterns may be observed elsewhere. 
Our choice of a serum creatinine <2 mg/dL for inclusion in the 
control group does not ensure normal renal function. However, 
this level would be unusual in a patient with moderate to severe 
renal failure.
Previous studies have identified both carbapenem resistance 
and chronic RRT as risk factors for poor outcomes during infec-
tion episodes. Gram-negative multidrug resistance has been 
previously associated with increased mortality in bacteremic epi-
sodes, and chronic RRT has been associated with increased risk 
of acquiring MDR infection and an increased risk of death. Here 
we show that chronic RRT is associated with higher mortality 
in CRE infections compared with control CRE-infected patients 
with serum creatinine <2 mg/dL. Furthermore, by DOOR ana-
lysis, we show that RRT patients have a 68% likelihood of an 
overall worse outcome. Beyond the human and financial costs 
of increased levels of care at discharge, this analysis highlights 
the impact of spread of CRE to nursing homes, LTACH, and, 
in chronic RRT patients, RRT centers. Because CRE infections 
result in such high levels of morbidity and mortality, further 
attention is needed to prevent infection by CRE, particularly in 
the RRT population and in the RRT centers they frequent.
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